BiotechTube

BYM338 + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sporadic Inclusion Body Myositis

Conditions

Sporadic Inclusion Body Myositis

Trial Timeline

Aug 1, 2011 → May 1, 2012

NCT ID
NCT01423110

About BYM338 + Placebo

BYM338 + Placebo is a phase 2 stage product being developed by Novartis for Sporadic Inclusion Body Myositis. The current trial status is completed. This product is registered under clinical trial identifier NCT01423110. Target conditions include Sporadic Inclusion Body Myositis.

What happened to similar drugs?

0 of 1 similar drugs in Sporadic Inclusion Body Myositis were approved

Approved (0) Terminated (0) Active (1)
🔄Bimagrumab + PlaceboNovartisPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT01868685Phase 2Withdrawn
NCT01601600Phase 2Completed
NCT01423110Phase 2Completed

Competing Products

7 competing products in Sporadic Inclusion Body Myositis

See all competitors
ProductCompanyStageHype Score
Bimagrumab + PlaceboNovartisPhase 3
40
BYM338 (Bimagrumab)NovartisPhase 2/3
38
BYM338/bimagrumab + PlaceboNovartisPhase 2/3
38
EverolimusNovartisPhase 2
27
LDE225 0.75% + VehicleNovartisPhase 2
27
Vandetanib 300 mgSanofiPre-clinical
26
REGN2477+REGN1033 + Matching placeboRegeneron PharmaceuticalsPhase 2
27